<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321408</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2019-24</org_study_id>
    <nct_id>NCT04321408</nct_id>
  </id_info>
  <brief_title>OP2C : Prialt® Observatory in Clinical Practice</brief_title>
  <acronym>OP2C</acronym>
  <official_title>OP2C : Prialt® Observatory in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Keocyt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ziconotide is a powerful analgesic marketed since 2009 in France and reserved for the
      intrathecal route.

      It is particularly effective on neuropathic pain and its main advantages are its power of
      action, the absence of spinal toxicity and the absence of respiratory depression. In
      addition, there were no signs of withdrawal when stopping the drug or tachyphylaxis.

      However, during these studies many undesirable effects were highlighted, especially
      neuropsychic which limited its use. This toxicity was mainly related to the administration of
      too high doses.

      In recent years, the use of ziconotide intrathecally has again become a relevant option.
      Indeed, it is recommended as a first line in the intrathecal treatment options.

      However, there is a lack of data on the current use of ziconotide in current practice.

      The objective of the study will be to describe the practical methods of using intrathecal
      treatments containing ziconotide.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Describe the practical methods of using intrathecal treatments containing ziconotide</measure>
    <time_frame>1 year</time_frame>
    <description>indication, initial intrathecal analgesic treatment and evolution of intrathecal analgesic treatment and monitoring.</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Refractory Pain</condition>
  <condition>Intrathecal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziconotide Injection</intervention_name>
    <description>intrathecal analgesia with Ziconotide</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with refractory pain treated with intrathecal analgesia containing ziconotide.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Severe refractory chronic pain

          -  Candidate for intrathecal analgesia treatment with ziconotide

          -  Patient informed about the study and who does not oppose it

        Exclusion Criteria:

          -  Contraindications to ziconotide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DENIS DUPOIRON, MD</last_name>
    <phone>+33 241352700</phone>
    <phone_ext>+33</phone_ext>
    <email>denis.dupoiron@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARINE TIGREAT</last_name>
    <phone>+33 240679878</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.tigreat@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>JESUS DIAZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Breteche</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>SYLVAIN DURAND, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital - Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>NAOUFEL OUERCHEFANI, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ziconotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziconotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

